Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prothena (PRTA)
NASDAQ:PRTA
Prothena (PRTA) Stock Price & Analysis
541 Followers
PRTA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.69 - $70.09
Previous Close$23.58
Volume325.37K
Average Volume (3M)533.29K
Market Cap
$1.27B
Enterprise Value$660.98M
Total Cash (Recent Filing)$618.80M
Total Debt (Recent Filing)$11.84M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Aug 07, 2024EPS Estimate
-$1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding53,771,845
10 Day Avg. Volume763,244
30 Day Avg. Volume533,292
Standard Deviation0.26
R-Squared0.00228
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.06
Price to Sales (P/S)12.64
Price to Cash Flow (P/CF)-5.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.23
Enterprise Value/Gross Profit7.23
Enterprise Value/Ebitda-18.67
Forecast
1Y Price Target
$69.83Price Target Upside196.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Prothena News
PremiumCompany Announcements
Prothena Shareholders Approve Incentives and Governance Measures
Bulls Say, Bears Say
Bulls Say
Collaborative RelationshipsBMY's continued interest and dialogue with PRTA suggests a strong collaborative relationship and potential for future developments.
Drug DevelopmentPRTA is now dosing at the highest dose cohort of 400mg for PR012 without safety concerns, suggesting a positive outlook for the drug's efficacy and safety profile.
Financial PerformanceThe company ended the quarter with a strong cash position and expects year-end cash to be substantial.
Bears Say
Financial ProjectionsRisk-adjusted, DCF-derived price target lowered to $83 from $85, after aligning YE cash projection with guidance.
Price Target ReductionThe price target for the company has been reduced to $84 from $90.
Program UpdatesThe stock has been under pressure due to investor focus on the PRX012 program updates.
---
Ownership Overview
49.08% Insiders
33.10% Mutual Funds
9.19% Other Institutional Investors
8.62% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $18.69 and its highest was $70.09 in the past 12 months.
What is Prothena’s market cap?
Currently, no data Available
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Aug 07, 2024 which is in 12 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on May 08, 2024. The company reported -$1.34 earnings per share for the quarter, missing the consensus estimate of -$1.158 by -$0.182.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -$1.06.
How many shares outstanding does Prothena have?
Prothena has 53,771,847 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -$1.34 in its last earnings report, missing expectations of -$1.158. Following the earnings report the stock price went down -4.472%.
Which hedge fund is a major shareholder of Prothena?
Among the largest hedge funds holding Prothena’s share is Platinum Investment Management. It holds Prothena’s shares valued at 1M.
---
Prothena Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.83 (196.14% Upside)
$69.83 (196.14% Upside)
Blogger Sentiment
Bullish
PRTA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 337.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.55%
12-Months-Change
Fundamentals
Return on Equity
-31.07%
Trailing 12-Months
Asset Growth
-15.96%
Trailing 12-Months
Company Description
Prothena
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
---
PRTA Company Deck
---
PRTA Earnings Call
Q4 2024
0:00 / 0:00
---
PRTA Stock 12 Month Forecast
Average Price Target
$69.83
▲(196.14% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
FibroGen
―
Best Analysts Covering PRTA
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+2.98%
assigned a buy rating 2 months ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +2.98% per trade.
---